Abstract: A parallel opening hinge includes a pair of parallel hinges, each parallel hinge having a moveable pivot within a track of the parallel opening hinge, wherein a connector joins the two movable pivots in the track such that the movable pivots move together.

Abstract: A parallel opening hinge includes tracks pivotally connected crossing links, wherein each pair of crossing links is mounted to the tracks via a fixed pivot and a movable pivot in each track. A connector joins two movable pivots in a track such that the movable pivots move together. Improved opening of a parallel opening vent can thereby result. A pivot between links of the hinge includes a fastener holding the links together and a bushing acting on the fastener to define spacing between the links.

Abstract: A parallel opening hinge includes tracks pivotally connected crossing links, wherein each pair of crossing links is mounted to the tracks via a fixed pivot and a movable pivot in each track. A connector joins two movable pivots in a track such that the movable pivots move together. Improved opening of a parallel opening vent can thereby result. A pivot mount for a link of the hinge includes a support block and a pivot pin engaging the support block, wherein the pivot pin includes a cam surface for abutting a link of a hinge in use to move the link relative to the support block.

Abstract: A system for and method of providing mobile device management. The system and method may include identifying, to a customer, a mobile management system that is communicatively coupled to a customer system associated with the customer via a first network and communicatively coupled to a plurality of mobile devices associated with the customer via a second network, storing, on the mobile management system, a plurality of template mobile applications, receiving, from the customer system, modification data associated with one of the plurality of template mobile applications via the first network, modifying the one of the plurality of template mobile applications based on the modification data, and transmitting, to the plurality of mobile devices, the modified one of the plurality of template mobile applications via the second network.

Abstract: A parallel opening hinge (1) comprises a first track (3), a second track (5) and at least two pairs of pivotally connected crossing links (7, 9), wherein each pair of crossing links (7, 9) is mounted to the tracks (3, 5) via a fixed pivot (13, 17) and a movable pivot (15, 19) in each track (3, 5), wherein a connector (23) joins two movable pivots (15) in a track (5) such that the movable pivots (15) move together. Improved opening of a parallel opening vent can thereby result. Other improved features of a parallel opening hinge are also described.

Abstract: A parallel opening hinge (1) comprises a first track (3), a second track (5) and at least two pairs of pivotally connected crossing links (7, 9), wherein each pair of crossing links (7, 9) is mounted to the tracks (3, 5) via a fixed pivot (13, 17) and a movable pivot (15, 19) in each track (3, 5), wherein a connector (23) joins two movable pivots (15) in a track (5) such that the movable pivots (15) move together. Improved opening of a parallel opening vent can thereby result. Other improved features of a parallel opening hinge are also described.

Abstract: This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ intermediates of the NHE-1 inhibitors and a new almost colorless form of the NHE-1 inhibitor N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine.

Abstract: This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ 1

Abstract: A novel process intermediate, tetrahydro-4-[3-(4-fluorophenyl)thio]phenyl-2H-pyran-4-carboxamide, of the formula: is described, as well as its use in a process of preparing 5-lipoxygenase inhibitors of the formula: which comprises establishing a reaction mixture consisting of: and an electron deficient monocyclic or benzo-fused bicyclic N-heterocycle containing two nitrogen atoms of the formula:  in an aprotic solvent; in the presence of a carbonate of the formula: (M)2-CO3, where M is an alkali metal, Group 1/Ia element, selected from the group consisting of lithium, Li; sodium,Na; potassium, K; rubidium, Rb; and cesium, Cs; followed by heating of said reaction mixture under a nitrogen atmosphere; whereby there is produced the desired compound of the above-recited formula.

Abstract: process is described for preparing a compound of Formula (1.3.0): comprising: establishing a reaction mixture consisting of in an aprotic solvent; in the presence of a strong base in solid form selected from the group consisting of sodium hydroxide, NaOH; and potassium hydroxide, KOH;—and optionally—in the presence of a catalytic amount of cesium carbonate, Cs2CO3, or of a phase transfer catalyst, especially a quaternary ammonium salt or a phosphonium salt—followed by—heating said reaction mixture under a nitrogen atmosphere; whereby there is produced a compound of Formula (1.3.

Abstract: This invention relates to zopolrestat monohydrate and polymorphs thereof. This invention also relates to processes for preparing zopolrestat monohydrate, for preparing polymorphs thereof and for preparing anhydrous zopolrestat. This invention also relates to compositions comprising zopolrestat monohydrate and to methods of using zopolrestat monohydrate and compositions thereof to treat diabetic complications such as diabetic cataracts, diabetic retinopathy or diabetic neuropathy, lower blood lipid levels or blood uric level.

Abstract: The present invention relates to processes for the preparation of 3-(1-piperazinyl)-1,2-benzoisothiazole or its pharmaceutically acceptable salt and to novel intermediates used in the process.

Abstract: The present invention relates to a pro-drug of ziprasidone or pharmaceutically acceptable salts thereof, processes for its preparation, and pharmaceutical compositions and methods of treatment comprising said pro-drug.

Abstract: Processes for the synthesis of tigogenin beta-O-cellobioside heptaalkanoate which is an intermediate for the known hypo-cholesterolemic agent tigogenin beta-cellobioside. The process comprises reacting .alpha.-cellobiosyl bromide heptaalkanoate and .beta.-tigogenin in the presence of zinc fluoride or zinc cyanide under conditions capable of forming said tigogenyl .beta.-O-cellobioside heptaalkanoate. The analogous preparations of hecogenin .beta.-O-cellobioside heptaalkanoate 11-ketotigogenin .beta.-O-cellobioside heptaalkanoate, and diosgenin .beta.-O-cellobioside heptaalkanoate are also disclosed. The process provides both high .beta.-anomeric selectivity and high yields.

Abstract: A process for the synthesis of peracyl-1-O-steroidal-.beta.-cellobiosides that provides excellent .beta.-anomeric selectivity without the use of a metal salt promoter. The process comprises reacting heptaacyl-.beta.-D-cellobiosyl-1-fluoride and a trisubstituted silyl-3-O-steroid, wherein the steroid is tigogenin, hecogenin, 11-ketotigogenin or diosgenin in the absence of a metal salt under suitable conditions.

Abstract: Processes for the synthesis of tigogenin beta-O-cellobioside heptaalkanoate which is an intermediate for the known hypocholesterolemic agent tigogenin beta-cellobioside. The process comprises reacting .alpha.-cellobiosyl bromide heptaalkanoate and .beta.-tigogenin in the presence of zinc fluoride or zinc cyanide under conditions capable of forming said tigogenyl .beta.-O-cellobioside heptaalkanoate. The analogous preparations of hecogenin .beta.-O-cellobioside heptaalkanoate, 11-ketotigogenin .beta.-O-cellobioside heptaalkanoate, and diosgenin .beta.-O-cellobioside heptaalkanoate are also disclosed. The process provides both high .beta.-anomeric selectivity and high yields.